2-甲基-4-氨基-6-氯嘧啶 | 1749-68-4

• 物质功能分类: 医药中间体 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-甲基-4-氨基-6-氯嘧啶
• 中文别名: 6-氯-2-甲基嘧啶-4-胺；4-氨基-6-氯-2-甲基嘧啶；6-氯-2-甲基-4-嘧啶胺
• 英文名称: 4-amino-6-chloro-2-methylpyrimidine
• 英文别名: 6-chloro-2-methylpyrimidin-4-amine；2-methyl-4-amino-6-chloropyrimidine；4-Amino-6-chlor-2-methylpyrimidin；6-chloro-2-methyl-4-pyrimidinamine；6-chloro-2-methyl-4-aminopyrimidine
• CAS: 1749-68-4
• 化学式: C₅H₆ClN₃
• mdl: MFCD07782029
• 分子量: 143.576
• InChiKey: SSAYHQQUDKQNAC-UHFFFAOYSA-N

物化性质

• 熔点：
  189 °C
• 沸点：
  269.2±20.0 °C(Predicted)
• 密度：
  1.349±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  51.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xn
• 危险类别码：
  R22
• 海关编码：
  2933599090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Amino-6-chloro-2-methylpyrimidine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Amino-6-chloro-2-methylpyrimidine
CAS number: 1749-68-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H6ClN3
Molecular weight: 143.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-甲基-4-氨基-6-氯嘧啶 在 氯化亚砜 、 potassium carbonate 、 sodium hydroxide 作用下， 以 甲醇 、 水 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 生成 达沙替尼
  参考文献：
  名称：

  一种达沙替尼的制备方法

  摘要：

  本发明提供一种达沙替尼的制备方法，利用2‑溴噻唑‑5‑甲酸和2‑甲基‑4‑氨基‑6‑氯嘧啶为原料，经第一次取代反应、和4‑(2‑乙酰氧基)乙基哌嗪经第二次取代反应制备2‑[[6‑[4‑(2‑乙酰氧基乙基)‑1‑哌嗪基]‑2‑甲基‑4‑嘧啶基]氨基]‑5‑噻唑甲酸；然后和酰氯化试剂经酰氯化反、和2‑氯‑6‑甲基苯胺酰胺化反应，最后经水解反应脱除乙酰基制备达沙替尼。本发明方法原料价廉易得，成本低；工艺流程简短，操作安全简便，工艺废水产生量少，绿色环保；原料及中间产物稳定性适宜，反应活性和选择性高，反应条件易于实现，副反应少，所制达沙替尼杂质少、纯度和产率高，利于达沙替尼的工业化生产。

  公开号：

  CN109265455B
• 作为产物：
  描述：

  4,6-二羟基-2-甲基嘧啶 在 甲醇 、 氨 、 三氯氧磷 作用下， 生成 2-甲基-4-氨基-6-氯嘧啶
  参考文献：
  名称：

  Baddiley et al., Journal of the Chemical Society, 1943, p. 383,384

  摘要：

  DOI：
• 作为试剂：
  描述：

  2-甲基-4-氨基-6-氯嘧啶 、 N-(4-甲氧基苄基)-2-氯-N-(2-氯-6-甲基苯基)-1,3-噻唑-5-甲酰胺 在 2-甲基-4-氨基-6-氯嘧啶 作用下， 以83的产率得到N-(4-methoxybenzyl)-2-(6-chloro-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)-1,3-thiazole-5-carboxamide
  参考文献：
  名称：

  J. Med. Chem. 2004, 47, 6658-6661

  摘要：

  DOI：

文献信息

• FLAP MODULATORS
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：US20140221310A1

  公开（公告）日：2014-08-07

  The present invention relates to compounds of Formula (I), or a form thereof, wherein ring A, R 1 , L and R 2 are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.

  本发明涉及式（I）化合物，或其形式，其中环A，R1，L和R2如本文所定义，作为FLAP调节剂有用。该发明还涉及包含式（I）化合物的药物组合物。制备和使用式（I）化合物的方法也属于本发明的范围。
• [EN] FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES CONDENSÉS EN TANT QUE MODULATEURS DE RÉCEPTEUR D'OREXINE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2011050200A1

  公开（公告）日：2011-04-28

  Disubstituted 3,8-diaza-bicyclo[4.2.0]octane and 3,6-diazabicyclo [3.2.0]heptane compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.

  描述了二取代的3,8-二氮杂双环[4.2.0]辛烷和3,6-二氮杂双环[3.2.0]庚烷化合物，这些化合物可用作促进睡眠素受体的调节剂。这些化合物可能在药物组合物和治疗由促进睡眠素活性介导的疾病状态、紊乱和症状的方法中有用，比如失眠。
• Nucleophilic aromatic substitution reactions under aqueous, mild conditions using polymeric additive HPMC
  作者：Niginia Borlinghaus、Tharique N. Ansari、Leon H. von Garrel、Deborah Ogulu、Sachin Handa、Valentin Wittmann、Wilfried M. Braje

  DOI：10.1039/d1gc00128k

  日期：——

  nucleophilic aromatic subsitution (SNAr) reactions between various nucleophiles and electrophiles. The mild reaction conditions facilitate a broad functional group tolerance that can be utilized for subsequent derivatization for the synthesis of pharmaceutically relevant building blocks. The use of only equimolar amounts of all reagents and water as reaction solvent reveals the greenness and sustainability

  使用廉价的，良性的，和可持续的聚合物，在水中的羟丙基甲基纤维素（HPMC）使亲核芳族subsitution（S Ñ各种亲核和亲电子之间的Ar）的反应。温和的反应条件促进了宽泛的官能团耐受性，该耐受性可用于随后的衍生化以合成药学上相关的结构单元。仅等摩尔量的所有试剂和水作为反应溶剂的使用揭示了本文提出的方法的绿色和可持续性。
• [EN] AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE<br/>[FR] COMPOSÉS D'AZABENZOTHIAZOLE, COMPOSITIONS ET PROCÉDÉS D'UTILISATION
  申请人：HOFFMANN LA ROCHE

  公开号：WO2012035039A1

  公开（公告）日：2012-03-22

  Provided are compounds of Formula I, stereoisomers, tautomers, solvates, prodrugs and pharmaceutically acceptable salts thereof, wherein A, X, R1, R2, R4 and R5 are defined herein, a pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, and methods of 5 manufacturing a compound of Formula I.

  提供的是公式I的化合物，立体异构体，互变异构体，溶剂合物，前药和其药学上可接受的盐，其中A、X、R1、R2、R4和R5在此处被定义，包括公式I的化合物和药学上可接受的载体、辅料或载体的药物组合物，使用该化合物或组合物进行治疗的方法，以及制造公式I的化合物的方法。
• [EN] INHIBITORS OF PROTEIN KINASES<br/>[FR] INHIBITEURS DE PROTÉINE KINASES
  申请人：INGENIUM PHARMACEUTICALS GMBH

  公开号：WO2009047359A1

  公开（公告）日：2009-04-16

  Compounds of general Formula I, wherein R1, R2, R3, x, A and Ra are as defined herein are inhibitors of cyclin-dependent kinases and are useful for preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases.

  通式I的化合物，其中R1、R2、R3、x、A和Ra的定义如本文所述，是细胞周期依赖性激酶的抑制剂，可用于预防和/或治疗任何类型的疼痛、炎症性疾病、免疫性疾病、增殖性疾病、传染性疾病、心血管疾病和神经退行性疾病。